metaEvidence - mapping review

meta|evidence oncology

Living systematic review and meta-analysis

metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) 5
mNSCLC - L2 - adenocarcinoma cell
mNSCLC - L2 - all population 5
mNSCLC - L2 - EGFR high
mNSCLC - L2 - EGFR mutant 1
mNSCLC - L2 - EGFR wild type
mNSCLC - L2 - KRAS mutant
mNSCLC - L2 - KRAS wild type
mNSCLC - L2 - PDL1 negative 1
mNSCLC - L2 - PDL1 positive 7
non squamous cell - mNSCLC - L2
non squamous - mNSCLC - L2 - all population 1
non squamous - mNSCLC - L2 - EGFR mutant
non squamous - mNSCLC - L2 - PDL1 positive
non squamous - mNSCLC - L2 - wild type (WT)
squamous cell - mNSCLC - L2
squamous - mNSCLC - L2 - all population 1
squamous - mNSCLC - L2 - PDL1 positive

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

graph table EGM comparisons

click on circles to display study description...

CodeBreaK 200, 2022 NCT04303780

sotorasib (n=169) vs. docetaxel (n=151)

randomized controlled trial

Studied treatment

oral sotorasib (960 mg daily)

Control treatment

intravenous docetaxel (75 mg/m2 every 3 weeks)

Patients

metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)

Method

open-label

Remark

abstract ESMO

powered by vis.js Network